摘要
本研究首次在体内外观察了钙拮抗剂维拉帕米（ＶＰ）与抗癌新药米托蒽醌（ＤＨＡＤ）合用，对人腺样囊性癌ＡＣＣ－２细胞的作用。发现：无毒剂量的ＶＰ可显著增强ＤＨＡＤ对ＡＣＣ－２细胞增殖的抑制，两药合用对ＡＣＣ－０２细胞的细胞毒有协同效应。￣３Ｈ－ＴｄＲ掺入试验表明，ＶＰ可增强ＤＨＡＤ对ＡＣＣ－２细胞ＤＮＡ合成的抑制作用。两药合用后，ＤＨＡＤ对ＡＣＣ－２细胞ＤＮＡ合成的ＩＣ＿（５０）值下降３．３２倍。流式细胞仪分析显示，ＤＨＡＤ佐以ＶＰ明显增强对ＡＣＣ－２细胞Ｇ＿２Ｍ期的阻断作用。裸鼠体内抑瘤实验证实，ＶＰ（５０ｍｇ／ｋｇ）明显增强ＤＨＡＤ（２ｍｇ／ｋｇ）对ＡＣＣ－２种植瘤生长的抑制作用，抑瘤率由单用ＤＨＡＤ的５７．９％提高到８８．４％。结果提示，可以将ＶＰ作为ＤＨＡＤ的增效剂用于涎腺癌临床化疗，以提高治疗效果。
AbstractIn this study, we investigated the effects of com-bination of Ca￣(++) antagonist verapamil (VP) with anew anticancer agent, mitoxantrone (DHAD) on thegrowth of human adenoid cystic carcinoma cell (ACC- 2) in vitro and in vivo. Non- toxic VP enhancedthe cytotoxicity of DHAD in ACC- 2 cells and signifi-cantly inhibited the cell proliferation. VP potentiatedDHAD's inhibitory effect on incorporation of ￣3H-TdR into ACC- 2 cells. When combined use of VPwith DHAD, IC50 of DHAD on DNA synthesis de-creased by 3. 32 fold- FCM analysis showed that VPenhanced the block effect of DHAD on ACC- 2 cellcycle traverse, causing cell accumulation in the G2Mphase. In vivo study also proved that VP enhancedthe tumoricidal effect of DHADon ACC- 2 implantedto nude mice. The inhibitory rate of tumor growthwas increased from 57. 9% to 88. 4% when DHADwas administered with VP.(Original article on page262)
出处
《中华口腔医学杂志》
CAS
CSCD
北大核心
1994年第5期262-265,共4页
Chinese Journal of Stomatology
